Herceptin Hylecta coverage & cost help
Herceptin Hylecta · trastuzumab and hyaluronidase-oysk · provider-administered subcutaneous injection
No account, member ID, name, date of birth, diagnosis or email is needed to use this guide.
Herceptin Hylecta is not the same formulation as IV Herceptin.
The current U.S. label describes Herceptin Hylecta as a fixed-dose subcutaneous combination of trastuzumab and hyaluronidase-oysk for HER2-positive breast cancer. The label uses a 600 mg trastuzumab / 10,000 units hyaluronidase dose every three weeks. Coverage should be checked for the exact Herceptin Hylecta product rather than assuming that an authorization for IV trastuzumab automatically applies.
A common access problem is preferred-product management. Some plans publish preferred IV trastuzumab products and treat Herceptin Hylecta as non-preferred or subject to additional criteria. That does not mean every plan denies Herceptin Hylecta; the member-specific policy controls.
Ask whether the problem is clinical criteria, product preference, site of care or coding.
Confirm whether the exact product requires precertification and which breast-cancer documentation the plan requests.
Some plans prefer one or more IV trastuzumab biosimilars before a non-preferred trastuzumab product/formulation.
Provider-administered oncology drugs can be subject to site-of-care rules in addition to medical-necessity review.
Herceptin Hylecta has its own HCPCS identity. Verify the exact code, units and product actually administered before claim submission.
Published policies show why the exact product matters.
UnitedHealthcare: its 09/01/2026 shared Commercial/Individual Exchange oncology policy lists Kanjinti and Ogivri as preferred trastuzumab products and lists Herceptin Hylecta among non-preferred products for oncology indications. Its Medicare Advantage Part B step-therapy policy also lists Herceptin Hylecta as non-preferred relative to specified trastuzumab products. Always open the live member-applicable policy because plan type and effective date matter.
Aetna: its 2026 precertification list includes Herceptin Hylecta and HCPCS J9356. Aetna also publishes product-specific Medicare Part B criteria. That is evidence of a defined review pathway—not a guarantee that a particular member is covered.
J9356 identifies the product, but it does not tell you what the patient will owe.
Current payer materials identify J9356 for Herceptin Hylecta. The treatment site still needs to verify current units, benefit rules, authorization and claim instructions. MedicineCostHelp does not turn a public payment number into a personalized price: actual out-of-pocket cost can vary with the plan, deductible, coinsurance, site of care, secondary coverage and assistance.
Understand what drives patient cost → Learn about J-codes/HCPCS →
Use Genentech's official support pathways after the coverage path is clear.
Genentech lists Access Solutions for coverage/access support and the Genentech Patient Foundation for eligible people who lack adequate coverage or cannot afford their Genentech medicine. Program eligibility and terms can change; use the official program rather than a third-party summary.
Keep formulation and product preference straight.
The medicine may be only part of the problem.
Use the playbook that matches what is blocking treatment, then verify the current rule with the insurer, program or treatment site.
Approval is pending, expired or unclear.
Find the rule, status and next authorization step.
DENIEDFind the reason before appealing.
Separate medical-necessity, benefit, product and claim problems.
PREFERRED PRODUCTThe plan wants a different brand or biosimilar.
Understand product preference without making a treatment recommendation.
SITE OF CAREThe medicine may be covered, but the location is not.
Check network, site and authorization requirements.
COST TOO HIGHSeparate coverage from financial assistance.
Understand manufacturer support versus independent foundations.
CLAIM PROBLEMAuthorization was approved, but billing still failed.
Compare the approval with the product, site and claim that were billed.
Important
MedicineCostHelp is an educational navigation resource, not an insurer, prescriber or coverage determination. Do not switch products or formulations based on this page; the treating clinician and current plan requirements control treatment and authorization decisions. Sources were reviewed 2026-08-22. Verify the current official source before acting.
Reviewed August 22, 2026. Sources include the current U.S. label, manufacturer support, and published payer materials.